Outcome of Donor and Recipient Sex Match Versus Mismatch in Stem Cell Transplant Procedure

Ali, Natasha; Ullah, Hayat; Shaikh, Mohammad Usman; Adil, Salman Naseem

doi:10.2217/ijh-2019-0006

Cited by 4 publications

(1 citation statement)

References 21 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is, therefore, gratifying that female animals were included in more than one study. Although not specifically addressed in these studies, it is known from the field of cell transplantation that sex (mis)matches between the donor and recipient can affect the outcome ( Kim et al, 2016 ; Ali et al, 2019 ). Therefore, when translating this to clinical trials, the sex of the donor versus recipient, in addition to the human leukocyte antigen (HLA) match, should be taken into account.…”

Section: Mainmentioning

confidence: 99%

Non-human primate studies for cardiomyocyte transplantation—ready for translation?

von Bibra,

Hinkel

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Non-human primates (NHP) are valuable models for late translational pre-clinical studies, often seen as a last step before clinical application. The unique similarity between NHPs and humans is often the subject of ethical concerns. However, it is precisely this analogy in anatomy, physiology, and the immune system that narrows the translational gap to other animal models in the cardiovascular field. Cell and gene therapy approaches are two dominant strategies investigated in the research field of cardiac regeneration. Focusing on the cell therapy approach, several xeno- and allogeneic cell transplantation studies with a translational motivation have been realized in macaque species. This is based on the pressing need for novel therapeutic options for heart failure patients. Stem cell-based remuscularization of the injured heart can be achieved via direct injection of cardiomyocytes (CMs) or patch application. Both CM delivery approaches are in the late preclinical stage, and the first clinical trials have started. However, are we already ready for the clinical area? The present review concentrates on CM transplantation studies conducted in NHPs, discusses the main sources and discoveries, and provides a perspective about human translation.

show abstract

Section: Mainmentioning

confidence: 99%

Non-human primate studies for cardiomyocyte transplantation—ready for translation?

von Bibra,

Hinkel

2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia

Larue,

Labopin,

Schroeder

et al. 2024

HemaSphere

View full text Add to dashboard Cite

Information on late complications in patients with acute leukemia who have undergone allogeneic hematopoietic cell transplantation (HCT) is limited. We performed a left‐truncated analysis of long‐term survival in patients with acute leukemia who were alive and disease‐free 2 years after HCT. We included 2701 patients with acute lymphoblastic leukemia (ALL) and 9027 patients with acute myeloid leukemia (AML) who underwent HCT between 2005 and 2012. The 10‐year overall survival (OS) rate was 81.3% for ALL and 76.2% for AML, with the main causes of late mortality being relapse (ALL‐33.9%, AML‐44.9%) and chronic graft‐versus‐host disease (ALL‐29%, AML‐18%). At 10 years, HCT‐related mortality was 16.8% and 20.4%, respectively. Older age and unrelated donor transplantation were associated with a worse prognosis for both types of leukemia. In addition, transplantation in the second or third complete remission and peripheral blood HSC for ALL are associated with worse outcomes. Similarly, adverse cytogenetics, female donor to male patient combination, and reduced intensity conditioning in AML contribute to poor prognosis. We conclude that 2‐year survival in remission after HCT for acute leukemia is encouraging, with OS of nearly 80% at 10 years. However, the long‐term mortality risk of HCT survivors remains significantly higher than that of the age‐matched general population. These findings underscore the importance of tailoring transplantation strategies to improve long‐term outcomes in patients with acute leukemia undergoing HCT.

show abstract

Donor Characteristics Predict the Success of Allogeneic Hematopoietic Stem Cell Transplantation in Thalassemia Major: A Single-Center Analysis of 250 Patients

Raj

Swaminathan

Meena

et al. 2021

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Outcome of Donor and Recipient Sex Match Versus Mismatch in Stem Cell Transplant Procedure

Cited by 4 publications

References 21 publications

Non-human primate studies for cardiomyocyte transplantation—ready for translation?

Non-human primate studies for cardiomyocyte transplantation—ready for translation?

Long‐term outcome of 2‐year survivors after allogeneic hematopoietic cell transplantation for acute leukemia

Donor Characteristics Predict the Success of Allogeneic Hematopoietic Stem Cell Transplantation in Thalassemia Major: A Single-Center Analysis of 250 Patients

Contact Info

Product

Resources

About